{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:48:32Z","timestamp":1791146912192,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,9,3]]},"DOI":"10.1038\/bjc.2013.469","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T20:02:25Z","timestamp":1376424145000},"page":"1157-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment"],"prefix":"10.1038","volume":"109","author":[{"given":"D","family":"Groheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Giacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"de Roquancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cuvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Coussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Espi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"BFbjc2013469_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259\u2013267.","journal-title":"Br J Cancer"},{"key":"BFbjc2013469_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, G\u00f3mez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horv\u00e1th Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M NeoALTTO Study Team (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379: 633\u2013640.","journal-title":"Lancet"},{"key":"BFbjc2013469_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ (2010) FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imag 37: 181\u2013200.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"BFbjc2013469_CR4","doi-asserted-by":"crossref","unstructured":"Cochet A, Kerrou K, Nabholtz JM, Cachin F, Pierga JY, Champion L, Ferrero JM, Darcourt J, Petit T, Bourahla K, Bougnoux P, Baulieu JL, Dupre PF, Salaun PY, Bachelot TD, Mognetti T, Coeffic DE, Mesnard N, Coudert B, Berriolo-Riedinger A (2012) An open-label randomized, multicenter, phase II study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): Design description. J Clin Oncol 30: (): (Suppl; abstr TPS646).","DOI":"10.1200\/jco.2012.30.15_suppl.tps646"},{"key":"BFbjc2013469_CR5","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","volume":"26","author":"D Fuster","year":"2008","unstructured":"Fuster D, Duch J, Paredes P, Velasco M, Mu\u00f1oz M, Santamar\u00eda G, Fontanillas M, Pons F (2008) Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures. J Clin Oncol 26: 4746\u20134751.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013469_CR6","first-page":"60","volume":"53","author":"G Gebhart","year":"2012","unstructured":"Gebhart G, Flamen P, Robles Barba J, Holmes E, Garcia C, Cortes Romera M, Eidtmann H, Baselga J, Gamez Cenzano C (2012) FDG-PET\/CT for early prediction of response to neoadjuvant anti-HER2 therapies in HER2-positive breast cancer (BC) patients. J Nucl Med 53: 60 (Suppl; Abstracts)..","journal-title":"J Nucl Med"},{"key":"BFbjc2013469_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377\u2013384.","journal-title":"Lancet"},{"key":"BFbjc2013469_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25\u201332.","journal-title":"Lancet Oncol"},{"key":"BFbjc2013469_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2967\/jnumed.112.106864","volume":"54","author":"D Groheux","year":"2013","unstructured":"Groheux D, Giacchetti S, Delord M, Hindi\u00e9 E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espi\u00e9 M (2013a) 18F-FDG PET\/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54: 5\u201311.","journal-title":"J Nucl Med"},{"key":"BFbjc2013469_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00259-010-1660-5","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Espi\u00e9 M, Rubello D, Moretti JL, Hindi\u00e9 E (2011a) Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET\/CT: defining a clinical aim. Eur J Nucl Med Mol Imag 38: 419\u2013425.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"BFbjc2013469_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti JL, Porcher R, Espi\u00e9 M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindi\u00e9 E (2011b) Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imag 38: 426\u2013435.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"BFbjc2013469_CR12","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/cncr.28020","volume":"119","author":"D Groheux","year":"2013","unstructured":"Groheux D, Hatt M, Hindi\u00e9 E, Giacchetti S, De Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espi\u00e9 M (2013b) Estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography during neoadjuvant chemotherapy. Cancer 119: 1960\u20131968.","journal-title":"Cancer"},{"key":"BFbjc2013469_CR13","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espi\u00e9 M (2012a) Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst 104: 1879\u20131887.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2013469_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2967\/jnumed.111.094045","volume":"53","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, Vercellino L, Berenger N, Marty M, Espi\u00e9 M (2012b) Triple-negative breast cancer: early assessment with 18F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53: 249\u2013254.","journal-title":"J Nucl Med"},{"key":"BFbjc2013469_CR15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","volume":"30","author":"V Guarneri","year":"2012","unstructured":"Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB Study. J Clin Oncol 30: 1989\u20131995.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013469_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2967\/jnumed.112.108837","volume":"54","author":"M Hatt","year":"2013","unstructured":"Hatt M, Groheux D, Martineau A, Espi\u00e9 M, Hindi\u00e9 E, Giacchetti S, de Roquancourt A, Visvikis D, Cheze-Le Rest C (2013) Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54: 341\u2013349.","journal-title":"J Nucl Med"},{"key":"BFbjc2013469_CR17","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1093\/annonc\/mds071","volume":"23","author":"O Humbert","year":"2012","unstructured":"Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F (2012) Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 23: 2572\u20132577.","journal-title":"Ann Oncol"},{"issue":"13","key":"BFbjc2013469_CR18","first-page":"00002","volume":"S0960-9776","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vald\u00e9s Olmos RA (2013) FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast S0960-9776 (13): 00002\u201300007.","journal-title":"Breast"},{"key":"BFbjc2013469_CR19","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2013) Breast Cancer. Version 3 (2013). Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"BFbjc2013469_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","volume":"13","author":"JY Pierga","year":"2012","unstructured":"Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roch\u00e9 H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P (2012) Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 13: 375\u2013384.","journal-title":"Lancet Oncol"},{"key":"BFbjc2013469_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00259-011-1735-y","volume":"38","author":"C Rousseau","year":"2011","unstructured":"Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C, Ricaud M, Bridji B, Kraeber-Bod\u00e9r\u00e9 F (2011) FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imag 38: 1029\u20131036.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"BFbjc2013469_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1200\/JCO.2008.17.2650","volume":"27","author":"J Schwarz-Dose","year":"2009","unstructured":"Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27: 535\u2013541.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013469_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00280-012-2032-6","volume":"71","author":"TA Smith","year":"2013","unstructured":"Smith TA, Appleyard MV, Sharp S, Fleming IN, Murray K, Thompson AM (2013) Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased hexokinase II, glut1 and [(18)F]-FDG incorporation and changes in (31)P-NMR-detectable phosphomonoesters. Cancer Chemother Pharmacol 71: 473\u2013480.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2013469_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00259-009-1343-2","volume":"37","author":"ME Straver","year":"2010","unstructured":"Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, Vogel WV, Peeters MJ (2010) Feasibility of FDG PET\/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imag 37: 1069\u20131076.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"BFbjc2013469_CR25","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, Hasm\u00fcller S, Lebeau A, Kreienberg R, Camara O, M\u00fcller V, du Bois A, K\u00fchn T, Stickeler E, Harbeck N, H\u00f6ss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29: 3351\u20133357.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013469_CR26","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796\u20131804.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013469_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-011-1780-z","volume":"131","author":"Y Wang","year":"2012","unstructured":"Wang Y, Zhang C, Liu J, Huang G (2012) Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 131: 357\u2013369.","journal-title":"Breast Cancer Res Treat"},{"key":"BFbjc2013469_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF American Society of Clinical Oncology; College of American Pathologists (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118\u2013145.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bjc2013469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2013469","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2013469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T03:28:25Z","timestamp":1720754905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9,3]]}},"alternative-id":["BFbjc2013469"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.469","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,13]]},"assertion":[{"value":"18 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2013","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}